EOLS vs STOK: fair value comparison
Evolus, Inc. and Stoke Therapeutics, Inc. · Updated 2026-10-19
EOLS's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. STOK has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, STOK currently ranks higher by quality score.
| EOLS | STOK | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $7.10 | $24.17 |
| 12-month range | $3.94–$9.30 | $22.37–$38.35 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #109 of 301 Healthcare | #107 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: EOLS fair value analysis · STOK fair value analysis